Match!
Herbert Hurwitz
Genentech
401Publications
58H-index
23.5kCitations
Publications 401
Newest
#1Jeffrey Melson Clarke (Duke University)H-Index: 8
#2Gerard C. Blobe (Duke University)H-Index: 43
Last.Christel Rushing (Duke University)H-Index: 10
view all 0 authors...
Purpose This study aimed to evaluate the maximum tolerated dose (MTD) and recommended phase II dose (RPTD), as well as the safety and tolerability of PF-03446962, a monoclonal antibody targeting activin receptor like kinase 1 (ALK-1), in combination with regorafenib in patients with refractory metastatic colorectal cancer.
#1Tomasz Burzykowski (UCL: Université catholique de Louvain)H-Index: 34
#2Elisabeth Coart (UCL: Université catholique de Louvain)H-Index: 2
Last.Charles S. Fuchs (Harvard University)H-Index: 124
view all 27 authors...
Importance Tumor measurements can be used to estimate time to nadir and depth of nadir as potential surrogates for overall survival (OS). Objective To assess time to nadir and depth of nadir as surrogates for OS in metastatic colorectal cancer. Design, Setting, and Participants Pooled analysis of 20 randomized clinical trials within the Aide et Recherche en Cancerologie Digestive database, which contains academic and industry-sponsored trials, was conducted. Three sets of comparisons were perfor...
#1Shodeinde A. Coker (BMS: Bristol-Myers Squibb)
#2Herbert Hurwitz (Duke University)H-Index: 58
Last.Lionel D. Lewis (Dartmouth–Hitchcock Medical Center)H-Index: 28
view all 7 authors...
Purpose To evaluate the effect of lapatinib on the QTc interval and ECG parameters in patients with advanced solid tumors.
#1Niharika B. Mettu (Duke University)H-Index: 3
#2Donna Niedzwiecki (Duke University)H-Index: 66
Last.Hope E. Uronis (Duke University)H-Index: 17
view all 10 authors...
Purpose This study was conducted to define the maximum tolerated dose (MTD), recommended phase two dose (RPTD), and toxicities of gemcitabine + dasatinib (GD) and gemcitabine + dasatinib + cetuximab (GDC) in advanced solid tumor patients.
#1Funda Meric-Bernstam (University of Texas MD Anderson Cancer Center)H-Index: 74
#2Herbert Hurwitz (Duke University)H-Index: 58
Last.Christopher Sweeney (Harvard University)H-Index: 59
view all 18 authors...
Summary Background Therapies targeting HER2 have improved clinical outcomes in HER2-positive breast and gastric cancers, and are emerging as potential treatments for HER2-positive metastatic colorectal cancer. MyPathway evaluates the activity of targeted therapies in non-indicated tumour types with potentially predictive molecular alterations. We aimed to assess the activity of pertuzumab and trastuzumab in patients with HER2 -amplified metastatic colorectal cancer. Methods MyPathway is an ongoi...
12345678910